Stocktoria
XOMA Royalty Corp XOMA
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 1986-06-06
XOMA Royalty Corp financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $52.1M | $28.5M | $4.8M | $6.0M | $38.2M |
| R&D expense | $1.7M | $2.9M | $143,000 | $153,000 | $171,000 |
| Operating income | $11.4M | -$40.0M | -$41.8M | -$17.4M | $17.5M |
| Income tax | $103,000 | -$5.7M | $0 | -$15,000 | $91,000 |
| Net income | $31.7M | -$13.8M | -$40.8M | -$17.1M | $15.8M |
| EPS (diluted) | $1.46 | $-1.65 | $-4.04 | $-1.98 | $0.65 |
| Operating cash flow | $2.9M | -$13.7M | -$18.2M | -$12.9M | $22.7M |
| Free cash flow | — | -$13.8M | -$18.2M | — | — |
| Cash & equivalents | $82.9M | $101.7M | $153.3M | $57.8M | $93.3M |
| Total assets | $272.7M | $221.3M | $234.3M | $140.4M | $166.6M |
| Total liabilities | $168.7M | $139.4M | $145.6M | $16.4M | $24.7M |
| Shareholders' equity | $83.9M | $61.9M | $88.7M | $124.0M | $141.9M |
Source: SEC EDGAR filings · CIK 0000791908 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.